Evotec joins NURTuRE-AKI consortium to advance kidney injury drug discovery
From Yahoo Finance: 2025-06-29 03:03:00
Evotec SE (NASDAQ:EVO) is considered one of the top 10 healthcare penny stocks to buy by analysts. The company will participate in the NURTuRE-AKI consortium to investigate acute kidney injury (AKI) and advance drug discovery using multi-omics approaches.
The NURTuRE-AKI consortium aims to establish a large patient cohort database for AKI to enhance understanding of its molecular mechanisms and accelerate drug discovery. Evotec, AstraZeneca, and Nephrolyx GmbH are industry partners supporting the consortium with £4.7 million, facilitated by Kidney Research UK.
Evotec will integrate the consortium’s data into its E.MPD platform and conduct omics analyses to identify biological mechanisms, molecular targets, and biomarkers for AKI. This partnership allows Evotec to leverage molecular insights for targeted drug discovery in AKI progression.
Evotec SE (NASDAQ:EVO) is a German biotechnology company specializing in drug discovery and development services for pharmaceutical and biotech companies globally. Its segments include Shared R&D and Just–Evotec Biologics for research services and biologics development.
While Evotec presents investment potential, other AI stocks may offer greater upside and lower downside risk. For more information on undervalued AI stocks and their benefits in the current market, consider exploring our free report on the best short-term AI stock.
Read more: Evotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug Discovery